Anika Therapeutics | ANIK - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 5.86B 675M 2026-03
Agenus USD 34.2M 4.61M 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 256.46M 38.78M 2026-03
Integra LifeSciences USD 213.21M 3.89M 2026-03
Intrexon USD -297K 167K 2024-06
J&J USD 17.24B 642M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Ligand Pharmaceuticals USD 48.45M 8.22M 2026-03
MacroGenics USD 31.11M 30.14M 2025-12
Merit Medical Systems USD 184.8M 10.56M 2026-03
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Smith & Nephew USD 2.09B 117M 2025-12
Stryker USD 3.81B 675M 2026-03
Surmodics USD 20.08M 31.62M 2025-06
Veracyte USD 101.16M 814K 2026-03
Xencor USD 21M 22.61M 2025-09
Zimmer Biomet Holdings USD 1.27B 8.1M 2025-12